Literature DB >> 11344217

The regulation of apoptosis by activin and transforming growth factor-beta in early neoplastic and tumorigenic ovarian surface epithelium.

K C Choi1, S K Kang, C J Tai, N Auersperg, P C Leung.   

Abstract

Most ovarian neoplasms arise from the ovarian surface epithelium (OSE), and multiple growth factors have been implicated to influence the transformation from OSE. The present study was performed to investigate the role of activin and transforming growth factor-beta (TGFbeta) in normal and neoplastic OSE cells. An immortalized OSE cell line (IOSE-29) was generated from normal OSE by transfecting simian virus 40 large T antigen and was rendered tumorigenic after subsequent transfection with the E-cadherin gene (IOSE-29EC). The activin/inhibin subunits and activin receptors were expressed at both messenger ribonucleic acids and protein levels in these cells, suggesting that activin may have an autocrine role in neoplastic OSE cells. Treatments with activin (1-100 ng/mL) resulted in a significant decrease in cell proliferation in both IOSE-29 and IOSE-29EC cells, although we have shown that it stimulated the growth of ovarian cancer cells and had no effect on normal OSE. This inhibitory effect was attenuated with cotreatment with follistatin. Treatment with TGFbeta (0.1-10 ng/mL) also significantly decreased the proliferation of normal, IOSE-29, and IOSE-29EC cells in a dose-dependent manner. In addition, treatments with both activin and TGFbeta resulted in an increase in DNA fragmentation in IOSE-29EC cells in a dose-dependent manner. This apoptotic effect of activin was attenuated by cotreatment with follistatin. Treatment with TGFbeta (1 and 10 ng/mL) resulted in a significant decrease in Bcl-2 protein (up to 50%) in IOSE-29EC, whereas no difference was observed in Bax protein levels. Therefore, down-regulated Bcl-2 by TGFbeta may eventually induce apoptosis in IOSE-29EC cells. In contrast, no difference was observed in Bax and Bcl-2 protein expression after treatment with activin. In conclusion, the present study indicates that activin and TGFbeta inhibited growth and induced apoptosis in early neoplastic (IOSE-29) and tumorigenic OSE (IOSE-29EC) cells. Furthermore, antiapoptotic Bcl-2 protein was down-regulated by TGFbeta, whereas no difference was produced in Bax protein by activin or TGFbeta treatment or in Bcl-2 protein by activin. These results suggest that activin and TGFbeta may play a role in growth inhibition and induction of apoptosis in early neoplastic and tumorigenic stage of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344217     DOI: 10.1210/jcem.86.5.7478

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling.

Authors:  Matthew Dean; David A Davis; Joanna E Burdette
Journal:  Cancer Lett       Date:  2017-01-20       Impact factor: 8.679

2.  Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance.

Authors:  Izabela Winkler; Barbara Wilczynska; Agnieszka Bojarska-Junak; Marek Gogacz; Aneta Adamiak; Krzysztof Postawski; Dorota Darmochwal-Kolarz; Tomasz Rechberger; Jacek Tabarkiewicz
Journal:  J Ovarian Res       Date:  2015-06-17       Impact factor: 4.234

3.  TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells.

Authors:  Jung-Chien Cheng; Nelly Auersperg; Peter C K Leung
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

4.  Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression.

Authors:  Ha-Yeon Shin; Wookyeom Yang; Eun-Ju Lee; Gwan Hee Han; Hanbyoul Cho; Doo Byung Chay; Jae-Hoon Kim
Journal:  PLoS One       Date:  2018-10-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.